5//SEC Filing
Boissel Stephane 5
Accession 0001209191-20-008969
CIK 0001001233other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 6:33 PM ET
Size
10.3 KB
Accession
0001209191-20-008969
Insider Transaction Report
Form 5
Boissel Stephane
EVP, Corporate Strategy
Transactions
- Expiration
Free Shares Call Options (obligation to sell to Issuer)
2019-07-03−1→ 3 totalFrom: 2019-05-03Exp: 2019-07-03→ Common Stock
Footnotes (1)
- [F1]In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person granted to the Issuer, effective November 27, 2018, the right to purchase up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning May 3, 2019 (the "Free Shares Call Options"). The exercise price per Subject Free Share to be paid by the Issuer upon any exercise of its Free Shares Call Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Issuer notifies the Reporting Person of its exercise of its Free Shares Call Options (as converted to euros) divided by 12.8329. On July 3, 2019, the Free Shares Call Option with respect to the first tranche of Subject Free Shares (or 52,700 Subject Free Shares) expired unexercised.
Issuer
SANGAMO THERAPEUTICS, INC
CIK 0001001233
Entity typeother
Related Parties
1- filerCIK 0001755198
Filing Metadata
- Form type
- 5
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 6:33 PM ET
- Size
- 10.3 KB